Patent application number | Description | Published |
20100048890 | CONJUGATED SMALL MOLECULES - Provided herein are linker compounds and conjugates that include the linker compounds. In one embodiment, the linker compounds comprise 2 or 3 residues of 6-aminohexanoic acid and optionally 7-10 residues of polyethyleneglycol (PEG). The linker compounds are useful in forming conjugates with one or more components useful in biopharmaceutical or bioanalytical applications. In particular, the biopharmaceutically useful compounds are kinase inhibitors. The conjugates described herein have utility in a variety of diagnostic, separation, and therapeutic applications. | 02-25-2010 |
20100173917 | UREA DERIVATIVES AS ABL MODULATORS - The invention provides methods and compositions for treating conditions mediated by Bcr-Abl. The invention also provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects. | 07-08-2010 |
20110118245 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O) | 05-19-2011 |
20120071535 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 03-22-2012 |
20130012561 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 01-10-2013 |
20130231333 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 09-05-2013 |
20140045868 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. | 02-13-2014 |
20140364427 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 12-11-2014 |
20150105403 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. | 04-16-2015 |
Patent application number | Description | Published |
20080261295 | Cell Sorting System and Methods - Apparatus and Methods are provided for a microfabricated fluorescence activated cell sorter based on a switch for rapid, active control of cell routing through a microfluidic channel network. This sorter enables low-stress, highly efficient sorting of populations of small numbers of cells (i.e., 1000-100,000 cells). The invention includes packaging of the microfluidic channel network in a self-contained plastic cartridge that enables microfluidic channel network to macro-scale instrument interconnect, in a sterile, disposable format. Optical and/or fluidic switching forces are used alone or in combination to effect switching. | 10-23-2008 |
20140371083 | SYSTEMS, APPARATUS AND METHODS FOR BIOCHEMICAL ANALYSIS - Systems, apparatus and methods are provided for biochemical analysis of a sample (e.g., a cell or nucleic acids). Samples are analyzed for molecular information and remain accessible for subsequent analysis or testing. The systems, apparatus and methods and systems provided are useful for performing quantitative and highly parallel biochemical reactions on biological samples in a high-throughput manner. | 12-18-2014 |
20150024476 | CELL SORTING SYSTEM AND METHODS - Apparatus and Methods are provided for a microfabricated fluorescence activated cell sorter based on a switch for rapid, active control of cell routing through a microfluidic channel network. This sorter enables low-stress, highly efficient sorting of populations of small numbers of cells (i.e., | 01-22-2015 |
Patent application number | Description | Published |
20100003267 | ANTI-ANGIOGENIC COMPOUNDS - The present invention provides VEGF binding peptides. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules. Various uses of the peptides and compounds are provided, including methods to treat disorders associated with abnormal angiogenesis. | 01-07-2010 |
20110087010 | ANTI-ANGIOGENIC COMPOUNDS - The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis. | 04-14-2011 |
20120301431 | METHODS OF TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS - The present invention provides methods of treating (including preventing) a disease or condition associated with abnormal angiogenesis in a subject include administering a therapeutically effective amount of an AA targeting compound of the invention to the subject. The AA targeting compounds comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. | 11-29-2012 |
20120321591 | ANTI-ANGIOGENIC COMPOUNDS - The present invention provides various uses of VEGF binding peptides, including methods to treat disorders associated with abnormal angiogenesis. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules | 12-20-2012 |
20150057431 | COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS - The present invention provides methods of treating (including preventing) a disease or condition associated with abnormal angiogenesis in a subject include administering a therapeutically effective amount of an AA targeting compound of the invention to the subject. The AA targeting compounds comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. | 02-26-2015 |
Patent application number | Description | Published |
20140269356 | REDUCING THE FREQUENCY OF MEASUREMENT OF A STATIONARY UE - A system and method reduce the frequency for performing measurements by a UE in a wireless network, such as a TD-SCDMA network. A UE compares at least one serving cell signal strength to a first threshold value. When the serving cell signal strength value is above the first threshold, the UE determines whether it is stationary. The UE determines whether it is stationary by evaluating change in serving cell signal strength and evaluating a timing difference value. The UE reduces the frequency for performing measurement(s) when changes in the serving cell signal strength values are below a second threshold value and the timing difference value is below a third threshold value. The timing difference can be a subframe number to subframe number (SFN-SFN) observed time difference. | 09-18-2014 |
20140269522 | ADAPTIVE CLOCK RATE FOR HIGH SPEED DATA COMMUNICATIONS - A method adaptively adjusts an internal clock rate and/or supply voltage based on an indication from a scheduling channel. A UE determines whether high speed data has been scheduled. The UE adjusts the clock speed and/or supply voltage based on the determination. | 09-18-2014 |
20150016349 | METHODS AND APPARATUS FOR ENHANCED UPLINK COMMUNICATION - Methods and apparatus for wireless communication at a user equipment (UE) include sending an uplink enhancement message to a network entity when an uplink enhancement condition has been detected. Further, the methods and apparatus include receiving communication from the network entity in response to sending the uplink enhancement message. Moreover, methods and apparatus for wireless communication at a network entity include detecting an uplink enhancement condition. Additionally, the methods and apparatus include transmitting a network entity originated uplink enhancement message to a UE in response to detecting the uplink enhancement condition. | 01-15-2015 |
20150103750 | METHODS AND APPARATUS FOR ENHANCED DOWNLINK COMMUNICATION - Methods and apparatus for wireless communication at a user equipment (UE) include sending a downlink enhancement message to a network entity when a downlink enhancement condition has been detected. Further, the methods and apparatus include receiving communication from the network entity in response to sending the downlink enhancement message. Moreover, methods and apparatus for wireless communication at a network entity include detecting a downlink enhancement condition. Additionally, the methods and apparatus include transmitting a network entity originated downlink enhancement message to a UE in response to detecting the downlink enhancement condition. | 04-16-2015 |